Drug data last refreshed 9h ago · AI intelligence enriched 3w ago
SOLAGE is a topical solution approved in 1999 for an undisclosed indication, manufactured by Almirall. The specific mechanism of action and patient population remain unspecified in available data.
Product approaching loss of exclusivity with moderate competitive pressure (30% intensity), suggesting shrinking team and transition toward generic transition planning.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Pilot Safety and Efficacy Study of Isolagen Therapy in Treatment of Restrictive Burn Scars
Safety and Efficacy Study of Isolagen TherapyTM in Treatment of Facial Wrinkles and Creases
Safety and Efficacy Study of Isolagen Therapy in the Treatment of Nasolabial Fold Wrinkles
Safety and Efficacy Study of Isolagen TherapyTM in the Treatment of Nasolabial Fold Wrinkles
Safety and Efficacy Study of Isolagen TherapyTM in Treatment of Interdental Papillary Insufficiency
Worked on SOLAGE at Almirall? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
SOLAGE currently shows zero linked job openings, reflecting its mature market position and approaching LOE status. Career opportunities center on defending market share and managing transition to generic competition, with limited growth or innovation-focused roles.